This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with metastatic breast cancer.
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging data on antibody–drug conjugate therapies into clinical practice for patients with metastatic breast cancer.
Upon completion of this activity, participants should be able to:
Compare the available antibody–drug conjugate therapies used in the treatment of metastatic breast cancer, considering antibody target, mechanism of action, overall construct, efficacy, and safety profile
Plan individualized treatment strategies for patients with HER2-low metastatic breast cancer, considering recent clinical data and expert recommendations
Select optimal second-line antibody–drug conjugate therapy for patients with HER2-positive metastatic breast cancer based on available clinical data and expert recommendations
Develop clinical strategies for the early identification and management of treatment-related symptoms associated with antibody–drug conjugates
Identify emerging targets for precision therapy with antibody–drug conjugates that may provide future treatment options for the treatment of metastatic breast cancer
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Rita Nanda, MD: researcher (paid to institution): Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate, OncoSec, Pfizer, Seattle Genetics, Taiho; advisor: AstraZeneca, BeyondSpring, Fuji Film, GE, Gilead, Infinity, iTeos, Merck, OBI Pharma, OncoSec, Sanofi, Seattle Genetics.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from August 21, 2023, through August 20, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-216-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to NABP CPE Monitor Service within 60 days.